Keywords
Sodium-glucose transporter 2 inhibitors
Heart failure
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the available evidence on the efficacy of SGLT2 inhibitors in preventing heart failure in adults with type 2 diabetes mellitus. Methods: This is an integrative literature review carried out through the PubMED, Virtual Health Library (VHL) and CAPES Periodical databases, using the descriptors: “Sodium-Glucose Transporter 2 Inhibitors”, “Prevention”, “Adults” and “Heart Failure” and obtaining the search truncation: (Sodium-Glucose Transporter 2 Inhibitors) AND (Prevention) AND (Heart Failure) AND (Adults). A total of 367 articles were found, filtered according to inclusion criteria (Portuguese, English and Spanish; period from 2020 to 2025; full articles) and exclusion (duplicate articles, abstracts, out of scope). Results: SGLT2 inhibitors effectively prevent heart failure in type 2 diabetics through multiple cardioprotective mechanisms that go beyond glycemic control, such as natriuresis and hemodynamic improvement. Final considerations: The response to treatment and the extent of benefits, including renal and cognitive protection, are influenced by patient characteristics, reinforcing their strategic and early use.
References
ALI UM, et al. The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta analysis. Cardiovascular diabetology, 2024; 23(1): 72.
BAVIERA M, et al. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Cardiovascular diabetology, 2022; 21(1): 162.
BIRKELAND KI, et al. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes, obesity & metabolism, 2021; 23(1): 75–85.
BITER HI, et al. The impact of using SGLT-2 inhibitor on left ventricular longitudinal strain and NT-proBNP levels during six-month follow-up in diabetic patients with and without coronary artery disease with preserved ejection fraction. Kardiologia polska, 2024; 82(6): 640–646.
CHAN YH, et al. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor. Cardiovascular diabetology, 2021; 20(1): 93.
CHEN K, et al. Time to benefit of sodium-glucose cotransporter-2 inhibitors among patients with heart failure. JAMA network open, 2023; 6(8): 2330754.
GAMAZA-CHULIÁN S, et al. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study. BMC cardiovascular disorders, 2021; 21(1): 456.
GIUGLIANO D, et al. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovascular diabetology, 2021; 20(1): 236.
KALE S e TAHRANI AA. Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention? Metabolism open, 2021; 10(100082): 100082.
KOHLMORGEN C, et al. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia, 2021; 64(8): 1834–1849.
LANGSLET G, et al. Empagliflozin use is associated with lower risk of all-cause mortality, hospitalization for heart failure, and end-stage renal disease compared to DPP-4i in Nordic type 2 diabetes patients: Results from the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) study. Journal of diabetes research, 2024; 6142211.
LEE HF, et al. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. Cardiovascular diabetology, 2020; 19(1): 160.
MAGURNO M, et al. Effects of SGLT2-inhibitors on comprehensive geriatric assessment, biomarkers of oxidative stress, and platelet activation in elderly diabetic patients with heart failure with preserved ejection fraction. International journal of molecular sciences, 2024; 25(16): 8811.
OSTROMINSKI JW, et al. Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease. European heart journal, 2025; 46(14): 1321–1331.
PALMIERO G, et al. Impact of SGLT2 inhibitors on heart failure: From pathophysiology to clinical effects. International journal of molecular sciences, 2021; 22(11): 5863.
REAL J, et al. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovascular diabetology, 2021; 20(1): 139.
SCHECHTER M, et al. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. Cardiovascular diabetology, 2021; 20(1): 169.
SEONG JM, et al. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. Cardiovascular diabetology, 2020; 19(1): 95.
SUZUKI Y, et al. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Cardiovascular diabetology, 2022; 21(1): 67.
TROMBARA F, et al. Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction. Cardiovascular diabetology, 2023; 22(1): 26.
UL AMIN N, et al. SGLT2 inhibitors in acute heart failure: A meta-analysis of randomized controlled trials. Healthcare (Basel, Switzerland), 2022; 10(12): 2356.
VADUGANATHAN M e JANUZZI JL. Preventing and Treating Heart Failure with Sodium-Glucose Co-transporter 2 inhibitors. The American journal of cardiology, 2019; 124(1): 20–27.
VISTISEN D, et al. Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia. Cardiovascular diabetology, 2023; 22(1): 233.
WANG W, et al. SGLT2 inhibitors are associated with reduced cardiovascular disease in patients with type 2 diabetes. Mayo Clinic proceedings. Mayo Clinic, 2023; 98(7): 985–996.
YANKAH RK, et al. Sodium-glucose cotransporter-2 inhibitors and cardiovascular protection among patients with type 2 diabetes mellitus: A systematic review. Journal of diabetes research, 2024; 9985836.